1. Scrip
  2. >>Conferences
  3. >>ESMO

ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return

 
• By Alexandra Shimmings

AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.    

Urinary System
• Source: Shutterstock

AstraZeneca PLC is one step further along the road to returning its PD-L1 inhibitor Imfinzi to the bladder cancer market following success in the Phase III NIAGARA trial that looked at its use peri-operatively in muscle-invasive patients eligible for surgery.

However, there may be bumps ahead. NIAGARA’s design leaves questions open as to where in the treatment process the checkpoint inhibitor was having the most impact, and what the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESMO

ESMO 24: SunRISes On J&J’s TAR-200 In Bladder Cancer

 
• By Alexandra Shimmings

J&J acquired Taris in 2019 to gain access to TAR-200 and its drug delivery platform. Now, early clinical data suggest the product could delay or remove the need for cystectomy in several bladder cancer settings and the US healthcare giant is eyeing multi-blockbuster sales.    

ESMO 24: CDK2 Inhibitors - Where Next For The Novel Class?

 
• By Alexandra Shimmings

The Barcelona meeting saw early data from two candidates from Incyte and Pfizer which suggest some progress for a new drug mechanism that has so far underwhelmed.    

ESMO 24: Investors Are Starting To Believe In BioNTech’s Cancer Drugs

 
• By Andrew McConaghie

The company’s investment in oncology is starting to pay off, with its PD-L1/VEGF inhibitor BNT324 generating particular interest at ESMO.

ESMO 24: Bayer Prostate Drugs Old And New Deliver On Survival

 
• By Kevin Grogan

The German group's goal of expanding Nubeqa into wider prostate cancer patient populations has probably been reached with the results from the Phase III ARANOTE study, while a combination of its older product Xofigo and Pfizer and Astellas’ Xtandi is set to become standard of care for another subset.

More from Conferences

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.